Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.
OBESITY RESEARCH SOLUTIONSBI-1467335 is an inhibitor of vascular adhesion protein-1 (VAP-1; IC50 = <100 nM), also known as semicarbazide-sensitive amine oxidase (SSAO), an enzyme with roles in leukocyte adhesion and transmigration.1 It is selective for VAP-1 over monoamine oxidase B (MAO-B) and diamine oxidase (DAO; IC50s = >1,000 and >10,000 nM, respectively). Oral administration of BI-1467335 (10 mg/kg per day) reduces plasma total cholesterol, LDL, and glucose levels, as well as decreases the recruitment of macrophages to atherosclerotic lesions and the area of atherosclerotic plaques, in a cholesterol-fed rabbit model.2 It reduces neutrophil lung infiltration induced by K. pneumoniae in mice when administered at a dose of 6 mg/kg.3 It also reduces airway hyperreactivity in a mouse model of rhinovirus-exacerbated allergy-induced asthma.
WARNING This product is not for human or veterinary use.
1. .
2. .
3. .